Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENG PHARMACEUTICAL CO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022026
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Announcement on the need to prepare the report on the use of the previously raised funds
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
According to the relevant provisions of the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on the report on the use of the previously raised funds (Zheng Jian FA FA Zi [2007] No. 500): “If a listed company applies for issuing securities and the time of receipt of the funds raised in the previous time is less than five fiscal years, the board of directors shall prepare a report on the use of the funds raised in the previous time in accordance with these Provisions, and report on the latest (domestic or overseas) of the deadline of the latest audited financial report of the issuance application document The actual use of the raised funds shall be described in detail, and the report on the use of the previously raised funds shall be submitted to the general meeting of shareholders for approval after making a resolution “.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”)
The arrival time of the raised funds is November 28, 2014. November 2014, Jingzhong
With the approval of the reply on approving Hunan Fangsheng Pharmaceutical Co.Ltd(603998) initial public offering of shares (zjxk [2014] No. 1188) issued by the Securities Regulatory Commission of the people’s Republic of China, the company issued 272 Shanghai Pudong Development Bank Co.Ltd(600000) ordinary shares (A shares) to the public for the first time, the issue price was 14.85 yuan / share, and the total amount of funds raised was 40481100000 yuan, After deducting the issuance expenses of 3512561776 yuan, the net amount of raised funds is 36968538224 yuan. The above raised funds were in place on November 28, 2014. Tianjian Certified Public Accountants (special general partnership) verified the arrival of the raised funds and issued the capital verification report (tianjianyan [2014])
2-30). As of December 31, 2017, the above raised funds have been used up.
In view of the fact that it has been more than five fiscal years since the company received the funds raised last time, and
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENG PHARMACEUTICAL CO., LTD.
In the last five fiscal years, the company has not raised funds through allotment, additional issuance and convertible corporate bonds. Therefore, the company does not need to prepare a report on the use of the funds raised in the previous time for this non-public offering of shares, nor does it need to hire an accounting firm with securities and futures related business qualifications to issue an assurance report on the use of the funds raised in the previous time.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
March 6, 2022
